Serap Pektaş, Osman Birol Özgümüş, İnci Durukan, Ümit Uzun, Ersin Karataş, A. Kiliç
{"title":"Stafilokkal Faj Endolizinlerinin Klonlanması, Rekombinant Olarak Üretilmesi ve Fonksiyonel Analizleri","authors":"Serap Pektaş, Osman Birol Özgümüş, İnci Durukan, Ümit Uzun, Ersin Karataş, A. Kiliç","doi":"10.59518/farabimedj.1255123","DOIUrl":null,"url":null,"abstract":"Staphylococci are pathogens that cause serious infections in humans and animals. Nosocomial infections caused by staphylococci, particularly methicillin-resistant Staphylococcus aureus (MRSA) strains, are mostly transmitted through healthcare workers, patients, or contaminated materials and food. In recent years, studies have been carried out to develop alternative antimicrobial strategies due to the inadequacy of existing antibiotics in the prevention of systemic, skin and implant-related biofilm infections caused by these multi-antibiotic resistant strains. One of these new approaches is the development of products containing the bacteriophage endolysin, which is particularly effective against multi-antibiotic-resistant bacteria. In this study, endolysin genes of bacteriophages (prophages) integrated into the chromosomes of Staphylococcus strains were amplified by polymerase chain reaction (PCR) and cloned into pET SUMO and pET-30b(+) vectors and produced recombinantly in E. coli. Recombinant endolysins were found to be anti-staphylococcal and antibiofilm effective against S. aureus, S. epidermidis and S. haemolyticus strains isolated from clinical specimens. These results show that endolysins have the potential to be used in the prevention of staphylococcal infections.","PeriodicalId":399200,"journal":{"name":"Farabi Tıp Dergisi","volume":"148 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Farabi Tıp Dergisi","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.59518/farabimedj.1255123","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Staphylococci are pathogens that cause serious infections in humans and animals. Nosocomial infections caused by staphylococci, particularly methicillin-resistant Staphylococcus aureus (MRSA) strains, are mostly transmitted through healthcare workers, patients, or contaminated materials and food. In recent years, studies have been carried out to develop alternative antimicrobial strategies due to the inadequacy of existing antibiotics in the prevention of systemic, skin and implant-related biofilm infections caused by these multi-antibiotic resistant strains. One of these new approaches is the development of products containing the bacteriophage endolysin, which is particularly effective against multi-antibiotic-resistant bacteria. In this study, endolysin genes of bacteriophages (prophages) integrated into the chromosomes of Staphylococcus strains were amplified by polymerase chain reaction (PCR) and cloned into pET SUMO and pET-30b(+) vectors and produced recombinantly in E. coli. Recombinant endolysins were found to be anti-staphylococcal and antibiofilm effective against S. aureus, S. epidermidis and S. haemolyticus strains isolated from clinical specimens. These results show that endolysins have the potential to be used in the prevention of staphylococcal infections.